Evidence map›Paper›PMID 34262020›Full record

ArticleCell death & disease2021

Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor.

Tom Delanghe, Jon Huyghe, Seungheon Lee, Dario Priem, Samya Van Coillie, Barbara Gilbert, Sze Men Choi, Peter Vandenabeele, Alexei Degterev, Gregory D Cuny and 2 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Tom DelangheVIB Center for Inflammation Research, 9052, Ghent, Belgium.
Jon HuygheVIB Center for Inflammation Research, 9052, Ghent, Belgium.
Seungheon LeeDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77204, USA.
Dario PriemVIB Center for Inflammation Research, 9052, Ghent, Belgium.ORCID 0000-0002-2527-1101
Samya Van CoillieVIB Center for Inflammation Research, 9052, Ghent, Belgium.
Barbara GilbertVIB Center for Inflammation Research, 9052, Ghent, Belgium.
Sze Men ChoiVIB Center for Inflammation Research, 9052, Ghent, Belgium.
Peter VandenabeeleVIB Center for Inflammation Research, 9052, Ghent, Belgium.ORCID 0000-0002-6669-8822
Alexei DegterevDepartment of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, MA, 02111, USA.
Gregory D CunyDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77204, USA.
Yves DondelingerVIB Center for Inflammation Research, 9052, Ghent, Belgium.
Mathieu J M BertrandVIB Center for Inflammation Research, 9052, Ghent, Belgium. mathieu.bertrand@irc.vib-ugent.be.ORCID 0000-0001-9000-0626
Ghent University · BEUniversity of Houston · USTufts University · US

Funding

Targeting RIPK3 in Flu-Associated Lung InjuryR01AI144400 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH, CUNY, GREGORY D · 2019 to 2023
$3.6M
Dissection of the new pro-inflammatory components of the necrosome complexR21AI124049 · NIAID · TUFTS UNIVERSITY BOSTON · PI DEGTEREV, ALEXEI, GERBER, SCOTT A. · 2017 to 2018
$466k
Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 12T9118NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1S02017NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) EOS MODEL-IDI 30826052Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G.0B96.20NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G.0C76.18NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G.0E04.16NNIAID NIH HHS R01 AI144400NIAID NIH HHS R21 AI124049Universiteit Gent (UGent) BOF20/IBF/039U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI124049U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI144400
6 · The paper itself

Abstract

Butylate hydroxyanisole (BHA) is a synthetic phenol that is widely utilized as a preservative by the food and cosmetic industries. The antioxidant properties of BHA are also frequently used by scientists to claim the implication of reactive oxygen species (ROS) in various cellular processes, including cell death. We report on the surprising finding that BHA functions as a direct inhibitor of RIPK1, a major signaling hub downstream of several immune receptors. Our in silico analysis predicts binding of 3-BHA, but not 2-BHA, to RIPK1 in an inactive DLG-out/Glu-out conformation, similar to the binding of the type III inhibitor Nec-1s to RIPK1. This predicted superior inhibitory capacity of 3-BHA over 2-BHA was confirmed in cells and using in vitro kinase assays. We demonstrate that the reported protective effect of BHA against tumor necrosis factor (TNF)-induced necroptotic death does not originate from ROS scavenging but instead from direct RIPK1 enzymatic inhibition, a finding that most probably extends to other reported effects of BHA. Accordingly, we show that BHA not only protects cells against RIPK1-mediated necroptosis but also against RIPK1 kinase-dependent apoptosis. We found that BHA treatment completely inhibits basal and induced RIPK1 enzymatic activity in cells, monitored at the level of TNFR1 complex I under apoptotic conditions or in the cytosol under necroptosis. Finally, we show that oral administration of BHA protects mice from RIPK1 kinase-dependent lethality caused by TNF injection, a model of systemic inflammatory response syndrome. In conclusion, our results demonstrate that BHA can no longer be used as a strict antioxidant and that new functions of RIPK1 may emerge from previously reported effects of BHA.

Indexed as

AnimalsAntioxidantsApoptosisButylated HydroxyanisoleDisease Models, AnimalFemaleFibroblastsFood AdditivesHT29 CellsHumansIntracellular Signaling Peptides and ProteinsMiceMice, Inbred C57BLMice, TransgenicMolecular Docking SimulationNecroptosisAntioxidantsButylated HydroxyanisoleFood AdditivesIntracellular Signaling Peptides and ProteinsProtein Kinase InhibitorsReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanRipk1 protein, mouseRipk3 protein, mouseSipl1 protein, mouseTNF protein, humanTnf protein, mouseTumor Necrosis Factor-alpha

Identifiers

PMID34262020
PMCPMC8280128
OpenAlexW3177784126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.